B+
Bull case
25%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-09-17 · RankAlpha Sentiment Codex
AMRX
AmnealBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Broad-based Q2 growth, raised guidance, expanding specialty products and the Kashiv biosimilar platform could sustain earnings growth and portfolio diversification. Debt repricing provides an additional earnings tailwind if its benefit is realized as planned.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.4.
What can break
A third-party September report described a shelf registration covering up to approximately $522.7 million of Class A shares; issuance is not established, but potential dilution warrants monitoring.
Momentum
93
Value
61
Sentiment
51
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $20.50 · Bull $24.00 · Bear $13.50Analysis 2026-09-17; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $22.71
Why
Momentum93 · Δ7d +1.0
Value61 · Δ7d -0.4
Sentiment51 · Δ7d -5.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.4.
Contradictions & invalidation
- • A third-party September report described a shelf registration covering up to approximately $522.7 million of Class A shares; issuance is not established, but potential dilution warrants monitoring.
- • August Form 4 filings show open-market sales by multiple officers or directors, including a large EVP sale; these transactions are not evidence of deteriorating operations but weaken the insider-signal backdrop. [#SEC-FORM4-2026-08-13] [#SEC-FORM4-2026-08-14]
- • The thesis depends on integrating and financing Kashiv while meeting uncertain regulatory milestones.
Catalyst clock
2026-12-16
Kashiv financing and debt-cost outcome
Lead driver: Value · See fundamentals
Momentum
93
8% active weight
Current posture
7d trendFlat
Δ7d
+1.0
Δ21d
+5.9
Value
61
47% active weight
Current posture
7d trendFlat
Δ7d
-0.4
Δ21d
-0.7
Sentiment
51
45% active weight
Current posture
7d trendSoftening
Δ7d
-5.4
Δ21d
-8.9
Why this grade
Composite grade B. Momentum 93.2 / Value 61.3 / Sentiment 51.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-17. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$20.50
Analysis reference price unavailable
Analysis 2026-09-17 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$13.50
Analysis reference price unavailable
Analysis 2026-09-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$6.51B
Beta
1.36
Shares Out
319.35M
P/E (TTM)
769.4
P/S (TTM)
1.36
P/FCF (TTM)
16.89
Rev YoY
+9.9%
EPS YoY
+152.8%
Gross Margin
+39.3%
Op Margin
+15.3%
Net Debt
$2.38B
Current Ratio
2.20
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data